GlassScriptPhysician profile
Matthew T Swiatowicz
NPI 1801150594
$11,086.93
in general payments reported to CMS, 2019-2025
49 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,392 · 2022: $2,166 · 2023: $2,326 · 2024: $2,333 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,528.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,333.08 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Insulet Corporation | $1,141.46 | 2021-2025 | Omnipod |
| Abbott Laboratories | $969.62 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $702.87 | 2021-2025 | |
| Dexcom, INC. | $677.32 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $612.46 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Radius Health, INC. | $566.28 | 2021-2025 | |
| Mannkind Corporation | $553.20 | 2021-2024 | Afrezza |
| Amgen INC. | $487.13 | 2021-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.88 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $460.82 | 2021-2024 | Farxiga |
| Tandem Diabetes Care, INC. | $316.35 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $279.59 | 2021-2023 | Tepezza |
| Abbvie INC. | $232.05 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $207.89 | 2021-2025 | Gvoke Hypopen |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $191.94 | 2021-2024 | Minimed 780g |
| Antares Pharma, INC. | $188.35 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Corcept Therapeutics | $123.28 | 2022-2024 | Korlym |
| Endo Pharmaceuticals INC. | $121.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $115.13 | 2021-2023 | Steglatro, Steglujan |
| Recordati_rare_diseases_inc. | $94.95 | 2021-2024 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $94.25 | 2021-2024 | Strensiq |
| Averitas Pharma INC. | $76.90 | 2024 | Qutenza |
| Ibsa Pharma INC. | $76.90 | 2021-2023 | Tirosint, Licart |
| Clarus Therapeutics INC. | $75.93 | 2021 | |
| Cequr Corporation | $74.84 | 2024-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $72.75 | 2022-2024 | |
| Amarin Pharma, INC. | $70.03 | 2021 | |
| Vivus LLC | $63.81 | 2021-2024 | Qsymia |
| Ascendis Pharma Endocrinology INC | $62.74 | 2023-2025 | Yorvipath |
| Halozyme INC | $61.43 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.18 | 2021 | |
| Grt US Holding, INC. | $50.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.20 | 2023 | |
| Lifescan, INC. | $45.49 | 2021 | |
| Amryt Pharma Holdings LTD | $33.90 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $29.24 | 2025 | |
| Madrigal Pharmaceuticals | $28.10 | 2024 | Resmetirom |
| Eusa Pharma (US) LLC | $24.03 | 2022 | |
| Chiesi USA, INC. | $23.57 | 2025 | Mycapssa |
| Ascensia Diabetes Care US INC. | $22.80 | 2023 | |
| Astellas Pharma US INC | $22.59 | 2024 | Veozah |
| Regeneron Healthcare Solutions, INC. | $22.56 | 2023 | Evkeeza |
| Almatica Pharma LLC | $22.46 | 2025 | Teriparatide |
| Endo USA, INC. | $22.36 | 2025 | Xiaflex |
| Beta Bionics, INC. | $22.14 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Verity Pharmaceuticals INC. | $16.30 | 2025 | Tlando |
| Acella Pharmaceuticals, LLC | $14.57 | 2025 | NP Thyroid 60 |
| Tolmar, INC. | $14.46 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Swiatowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.